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Abstract
Purpose—African American (AA) women have higher breast-cancer specific mortality rates. A 
higher prevalence of the worse outcome Basal-like breast cancer subtype contributes to this, but 
AA women also have higher mortality even within the more favorable outcomes Luminal A breast 
cancers. These differences may reflect treatment or health care access issues, inherent biological 
differences, or both.
Methods—To identify potential biological differences by race among Luminal A breast cancers, 
gene expression data from 108 CAU and 57 AA breast tumors were analyzed. Race-associated 
genes were next evaluated for associations with survival. Finally, expression of race- and survival-
associated genes was evaluated in normal tissue of AA and CAU women.
Results—Six genes (ACOX2, MUC1, CRYBB2, PSPH, SQLE, TYMS) were differentially 
expressed by race among Luminal A breast cancers and were associated with survival (HR < 0.8, 
HR > 1.25). For all six genes, tumors in AA had higher expression of poor prognosis genes 
(CRYBB2, PSPH, SQLE, TYMS) and lower expression of good prognosis genes (ACOX2, 
MUC1). A score based on all six genes predicted survival in a large independent dataset (HR = 1.9 
top vs. bottom quartile, 95% CI: 1.4 – 2.5). For four genes, normal tissue of AA and CAU women 
showed similar expression (ACOX2, MUC1, SQLE, TYMS), however, the poor outcome 
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associated genes CRYBB2 and PSPH were more highly expressed in AA vs. CAU women’s 
normal tissue.
Conclusions—This analysis identified gene expression differences that may contribute to 
mortality disparities and suggests that among Luminal A breast tumors there are biological 
differences between AA and CAU patients. Some of these differences (CRYBB2 and PSPH) may 
exist from the earliest stages of tumor development, or even precede malignancy.
INTRODUCTION
Compared to Caucasian (CAU) women, African American (AA) women have lower 
incidence, but higher breast cancer-specific mortality rates [1]. Higher prevalence of 
aggressive basal-like breast cancers in AA women [2] may explain some disparities, but 
even when AA women are diagnosed with less-aggressive Luminal A breast cancers, they 
fare worse than CAU women with the same subtype [3]. There are likely multiple factors 
contributing to the differences, including differential access to care [4] and lifestyle factors. 
There is some evidence that there may be biological differences in the tumors of AA versus 
CAU women, even within subtype. For instance, even after controlling for some 
socioeconomic status variables (SES) in a study where all women received the same 
treatment based on tumor characteristics, the Southwest Oncology Group [5] reported 
survival differences between CAU and AA women. Specifically, AA had a survival 
disadvantage compared with CAU women for ER+ premenopausal breast tumors [HR = 
1.74, 95% CI = (1.11, 2.71)] and ER+ postmenopausal breast cancer [HR = 1.61, 95% CI = 
(1.35, 1.93)]. While many social variables are difficult to study and the role of SES cannot 
be fully ruled out in such studies, it is clear that both social and biological factors should be 
considered.
Only a few studies [6–9] have characterized molecular differences in breast tumors by race. 
Martin et al [8] hypothesized that the tumor microenvironment differed between AA and 
CAU. They reported that independent of ER status, 19 and eight genes were differentially 
expressed in the breast tumor stroma and epithelium, respectively, of 18 AA and 17 CAU 
women. Grunda et al [7] evaluated expression of 84 genes associated with breast cancer 
aggressiveness, prognosis and response to therapy, and found that 20 of these genes were 
differentially expressed in 12 AA and 12 CAU age- and stage-matched breast tumors. Field 
et al [6] identified genes that were differentially expressed in 26 AA and 26 CAU age, grade 
and ER-matched breast tumors. They found that a few genes, including CRYBB2, PSPHL 
and SOS1, were differentially expressed in both normal and tumor tissue. Most recently, 
Stewart et al [9] analyzed age- and stage-matched breast tumors from the Tumor Cancer 
Genome Atlas (TCGA) project and reported 674 unique genes or transcripts that were 
differentially expressed by race. Despite matching on clinical features in the TCGA analysis, 
AA had a significantly higher risk of mortality compared with CAU women (18.87% vs 
10.28% - time period not given), and these investigators found gene expression differences 
among luminal A (46 genes), basal-like (15 genes) and HER2 (25 genes) among stage 1–3 
tumors and increasing numbers of differentially expressed genes with increasing stage (from 
26 in stage 1 to 223 in stage 3). The TCGA gene signatures were not evaluated for 
associations with survival nor tested in independent data.
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Each of these previous studies evaluated molecular features that may contribute to mortality 
disparities between AA and CAU breast cancer cases, however, we propose that a disparity-
associated gene should meet the following criteria: (1) the gene should be differentially 
expressed by race in the tumor, and this association should be not be driven solely by 
clinical features such as intrinsic subtype, ER status or patient age, (2) the differential 
expression of a candidate gene should be associated with a difference in breast cancer 
survival. If the gene is associated with race without consequences for survivorship, its utility 
in explaining mortality disparities is limited. We were also interested to know whether the 
gene was differentially expressed in normal because these gene expression differences are 
more likely to predate disease progression. Our goals were to extend previous studies by 
studying both expression and survival, to evaluate the joint effects of multiple disparity-
associated genes on survival, and to evaluate how the disparity–associated genes are 
expressed in normal tissue.
METHODS
Datasets and data preprocessing
We used several datasets that included tumor, tumor-adjacent normal and reduction 
mammoplasty gene expression data. Most of these data sources are publically available. 
Data characteristics, including Gene Expression Omnibus (GEO) accession numbers, are 
listed in Table 1. We used the UNC337 tumor gene expression dataset to evaluate race-
associated tumor gene expression. UNC337 is a racially diverse population (race 
information listed in Supplemental Table 3), while the NKI295 public dataset is racially 
homogenous (predominantly Caucasian European). Evaluating survival in an independent 
and racially homogenous population allows us to make broader inferences about the 
importance of relative gene expression on survival. We compared gene expression in normal 
(RM), cancer-adjacent normal and tumor (UNC337 + NKI295) datasets. Reduction 
mammoplasty samples were from previous reports [10, 11] and from the Normal Breast 
Study, a study of patients undergoing surgery at UNC Hospitals [12]. All patients provided 
informed consent via a protocol approved by the Institutional Review Board of the 
University of North Carolina at Chapel Hill. All four of these datasets were on the same 
expression platform (Agilent), allowing us to compare gene expression across tissue type. 
We used the METABRIC [13] dataset as an independent test dataset to evaluate the tumor-
based survival associations.
The isolation of RNA and methods of basic microarray processing are described in detail by 
Sun et al [10], Prat et al [14] and van de Vijver et al [15] for RM, UNC337 and NKI295 
respectively. Array filtering and cleaning of the RM and NKI295 datasets are described in 
Pirone et al [11]. From 149 microarrays, there were 130 unique RM samples, of which 100 
self-reported AA or CAU race. There were 92 cancer-adjacent, histologically normal 
samples of self-described CAU or AA women (NBS). Genes that were present (above 
detection limit) in fewer than 15% of samples were excluded. From the UNC337 data, we 
removed autopsies, samples without corresponding demographic and race information, and 
averaged all replicates by probe. Genes with more than 30% missing across all samples were 
excluded. We used k-nearest neighbors (KNN) (k=10) to impute missing data. Missing data 
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were imputed using k nearest neighbors (KNN) (k=10). Data for all the normal breast tissues 
(RM_NBS) were combined using distance-weighted discrimination (DWD) [16]. Data 
processing and analyses were completed using BioConductor and R Version 2.14.
Race-associated gene expression in tumor and normal tissue
Race-associated genes were identified in tumors overall and stratified by subtype. Tumors 
were classified into intrinsic subtype using the PAM50 [17]. Supervised analysis was 
performed on all subtypes in UNC337 after selection criteria, as described above, using 
Linear models for Microarray Data (LIMMA) [18] and a False Discovery Rate (FDR) of 
5%. Subtype-stratified supervised analyses were performed on N=68 Luminal A tumors and 
N=39 Basal-like tumors. Using Cluster 3.0 [19], we clustered the expression data by both 
gene and sample, and visualized the resulting cluster dendogram in Java Treeview [20]. For 
genes with multiple probes, we selected the probe with the highest standard deviation to 
display in the two dimensional cluster. We evaluated the statistical association between 
cluster and race using a Chi-square test. We performed sensitivity analyses wherein models 
were adjusted for tumor characteristics (grade, stage, node, age) to evaluate whether tumor 
characteristics confounded the association between race and gene expression.
LIMMA analyses were also used to identify genes associated with race in non-tumor tissue 
at an FDR = 5%. Since these samples included both cancer-adjacent normal and normal 
tissue (N=192) from two different populations, we statistically adjusted for data source in 
addition to performing DWD correction as described above.
NKI295 survival
We defined disparity-relevant gene expression as gene expression associated with race in the 
tumor and with survival in test data. The first criteria was met by identifying race-associated 
gene expression at an FDR = 5% in the UNC337 (Luminal A or Basal-like tumors) data. 
These genes were mapped to the NKI dataset, and were then extracted and median centered. 
We then performed a survival analysis that compared individuals with above-median 
expression to those with below-median (referent) expression for each of the race-associated 
genes. Two race-associated genes (FAM177A1, GSTT2) were not available in the NKI 
dataset. For each gene, we plotted Kaplan-Meier curves and estimated hazard ratios (HR) 
using Cox Proportional hazards models. A HR < 1 signifies that higher expression confers a 
survival advantage, whereas a HR >1 suggests that higher expression confers a survival 
disadvantage.
There were six race-associated genes that showed a high magnitude association (HR <0.8 or 
HR >1.25) with survival in the NKI295 dataset. These genes were used to create a Multi-
gene Race-associated Expression (MRE) score that varied between −6 and 6. A score of −6 
should predict the best survival and that of +6, the worst survival. We generated this score 
for each patient by summing up the “deleterious” effects of each race- and survival- 
associated gene. The deleterious effect was −1 when the patient level expression was below 
the median expression for genes with a HR > 1 or above the median expression for genes 
with a HR < 1. Similarly, the deleterious effect was +1 when the patient level gene 
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expression was above the median expression for genes with a HR > 1 or above the median 
expression for genes with HR < 1.
The association between the MRE score and survival was evaluated using Cox Proportional 
Hazards in both the training (NKI295 + UNC337, N=450) and independent (METABRIC, 
N=1584) dataset. We tested the statistical association between mean MRE score and tumor 
subtype in both datasets, and between CAU and AA tumors overall and in Luminal A 
tumors using either ANOVA (N > 2 groups) or Student T’s test (2 groups). We also assessed 
association between MRE score and survival among luminal tumors. Finally, we calculated 
tumor proliferation scores—a marker of tumor proliferation capability and defined as the 
sum of expression of the following genes: {CCNB1, UBE2C, BIRC5, KNTC2, CDC20, 
PTTG1, RRM2, MKI67, TYMS, CEP55, CDCA1}—for all tumors, and evaluated the 
association between this marker and the MRE score.
Evaluating gene expression changes by race and tissue type
Patterns of gene expression in normal and tumor tissue, stratified by race are informative for 
whether the differential expression is a disease feature or exists prior to carcinogenesis. 
Thus, we tested each of the tumor race- and survival-associated genes for their expression in 
reduction mammoplasty (N=100), cancer-adjacent normal (N=92) and tumor tissue 
(N=460). In datasets where there were multiple probes for a particular gene, we chose the 
probe that was differentially expressed in the UNC337 dataset if available. Alternatively, 
any probe mapping to the same gene was used if the specific probe was unavailable. We 
median centered the dataset of all three, tissue types and then plotted average relative 
expression in boxplots, stratified by race and tissue type.
RESULTS
Training data identification of race- and survival associated genes
Compared with CAU tumors (Table 2), AA tumors were more likely to be node positive 
(60% vs 42%, p = 0.03), ER negative (53% versus 31%, p = 0.03) and less differentiated 
(61% versus 46%, p = 0.10). At an FDR = 5%, there were 40 probes, representing 38 
distinct genes, that were differentially expressed by race across all tumors. A cluster of these 
38 genes (rows) and race (columns) is shown in Fig. 1. The left cluster (Cluster 1, N=63) 
was primarily composed of AA samples (N = 39, 62%), and the right cluster (Cluster 2, 
N=102) was predominately CAU samples (N = 84, 82%), (chi-square = 31.8, df = 1, p < 
1.7e-8).
To identify genes that were differentially expressed by race among less aggressive tumors 
(Luminal A), or more aggressive tumors (Basal-like), we performed two supervised analyses 
at an FDR = 10%, restricted to Luminal A or basal-like tumors. There were 23 genes 
differentially expressed by race at a 10% FDR among Luminal A tumors, of which 10 genes 
(Table 3a) were significant given 5% FDR. There were only two genes differentially 
expressed given 5% or 10% FDR in Basal-like tumors (Table 3b). We also adjusted for age, 
grade, size and node status in multivariable analyses (Supplemental Tables 1a–1b); among 
Luminal A breast cancers, most genes were still differentially expressed by race after 
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statistical adjustment including: CRYBB2, PSPH, MUC1, HSDL1, GSTT2, CLEC2D, 
FAM177A1. AMFR and PSPH remained differentially expressed by race among Basal-like 
tumors in multivariable model.
Among these race-associated genes, six were also associated with survival in the NKI295 
dataset. High expression of CRYBB2, PSPH, TYMS, and SQLE was associated with higher 
mortality, while low expression of MUC1 and ACOX2 predicted worse survival (Table 4). 
The CRYBB2 survival curves violated the proportional hazards assumption, with the 
crossover of the two curves occurring at ~8–10 years. This pattern of crossing hazards at 
~8–10 years has been previously documented among ER positive breast cancers [11]. Four 
other race-associated genes (AMFR, CLEC2D, HSDL1, SLC9A3R2) were not associated 
with survival in the NKI dataset (Supplemental Fig. 1).
Gene expression in normal versus tumor
To elucidate patterns of expression for race- and survival-associated genes from normal to 
tumor tissue, we evaluated expression of these genes in reduction mammoplasty, cancer-
adjacent normal and tumor. On average, expression was higher in tumors of AA compared 
to CAU for SQLE and TYMS, and lower in ACOX2 and MUC1 tumors comparing AA to 
CAU. However, the pattern of expression in the normal to tumor expression continuum was 
similar between CAU and AA (Figs. 2a–d). In contrast, both CRYBB and PSPH were 
differentially expressed by race in both normal and tumor tissue; higher gene expression 
among AA compared with CAU women (Figs. 2e–f). Higher expression of these genes by 
race in benign tissue was not substantially attenuated even after statistical adjustment for 
normal tissue type (normal versus adjacent-normal).
For all six MRE-associated genes, AA had higher expression of poor prognosis genes and 
lower expression of good prognosis genes (Table 4) compared with CAU. Higher relative 
expression of ACOX2 and MUC1 in tumors were each associated with a ~35% reduction in 
mortality (Table 4), and AA tended to have lower expression of these genes compared with 
CAU (Fig. 2a–b, Table 4). For CRYBB2, PSPH, TYMS and SQLE, higher relative gene 
expression was associated with increased mortality in the NKI295 dataset (Table 4, Figs. 
2a–b, 2e–f). In both CAU and AA women, gene expression of TYMS and SQLE increases 
dramatically from normal and adjacent-normal tissue to tumor tissue; however, the tumor 
expression was highest among AA women (Table 4, Fig. 2c–d). For PSPH and CRYBB2, 
gene expression increased from normal to tumor tissue among CAU women, whereas 
relative expression was higher in both tumor and normal of AA women.
Multi-gene Race-associated Expression (MRE) score
Applying the information learned from training on NKI data to an independent dataset, we 
computed MRE scores for all individuals in our test data (METABRIC, N=1584) and 
training data (NKI295+UNC337, N=450), where −6 = best and +6 = worst risk. Each 
increasing MRE point was associated with a 6% increase in hazard, HR = 1.06, 95% CI = 
(1.04, 1.09), such that the HR comparing a 6 point individual to a −6 point individual was 
2.03, 95% CI = (1.98, 2.08) in METABRIC. This result was attenuated when we adjusted 
for size, grade and node status (HR = 1.03, 95% CI = (1.00,1.06) for each increase in MRE 
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points), but remained statistically significant. We also observed strong associations for MRE 
score and survival when we restricted to N=401 Luminal tumors, with a HR = 1.76, 95% CI 
= (1.64, 1.89) for the comparison of an individual with a score of +6 to an individual with a 
score of −6. After adjustment for size, grade and node status, the association was: HR = 
1.36, 95% CI = (1.26, 1.46). Interestingly, high “MRE” scores were associated with Basal-
like tumors in both the training and test datasets (Fig. 3a–b). AA patients had a significantly 
higher (p < 0.001) MRE score (2.42) than Caucasians (−0.32) in our test dataset (NKI295 + 
UNC337) over all tumors (Fig. 3c), and specifically in Luminal A tumors (1.67 vs −2.43, p 
< 0.001) (Fig. 3d). Associations between MRE score and race could not be assessed in 
METABRIC due to the predominance of CAU patients in that dataset.
Although there was a monotonic increase in the hazard ratio with each increase in the MRE 
score, the largest increase in risk occurs with just a few gene expression changes; in our test 
dataset, patients with the middle 50% MRE scores (compared to those in bottom quartile) 
had a strong elevation in risk (HR = 1.7, 95% CI = (1.3, 2.1)), and those with the top quartile 
MRE scores had a HR = 1.9, 95% CI = (1.4, 2.5) compared to the bottom quartile (Fig. 4b). 
There associations were slightly attenuated results when we restricted to Luminal A/B 
tumors. Comparing those with the highest quartile MRE score and those with the middle 
50% of MRE score to the referent, lowest quartile group, there was a 50% [95% CI = (1.0, 
2.3)] and 60% [95% CI = (1.2, 2.1)] increase in hazard respectively (Fig. 4c). We were 
limited by a relatively small number of luminal A tumors with a high MRE score (Fig. 4d) 
to sufficiently examine the association between MRE score and survival among luminal A 
tumors. In sensitivity analyses (data not shown) we found that relative measures of 
association were much stronger in the METABRIC dataset when we restricted to women <= 
60 years of age. The UNC337 and NKI295 datasets are comprised predominantly of 
younger women so the attenuation of effect in test data may be partially attributed to 
population differences between the METABRIC and UNC337+NKI297 datasets.
Tumor proliferation scores were correlated with MRE points in both the training (ρ = .55, p 
< 0.001) and test (ρ = 0.59, p <0.001) datasets. Proliferation scores were significantly (p < 
0.001) higher in AA women (1.63) than in CAU women (−0.73) over all tumors in the 
UNC337 dataset, and in luminal A tumors (−0.99 AA versus −3.90 CAU, p < 0.001). It is 
important to note that the disparities score was attenuated but remained significant after 
adjusting for standard clinical variables, but was not significant after adjusting for breast 
cancer subtype (Table 5).
DISCUSSION
It has been established that AA women suffer from worse breast cancer outcomes compared 
to CAU women. While aggressive forms of BC disproportionately affect AA women, this 
does not fully explain the disparities; even within subtype there are differences in survival 
by race. From previous studies we have learned that: 1) survival differences exist between 
AA and CAU despite equal treatment [5] or tumor subtype [3] and 2) genes are differentially 
expressed between AA and CAU tumors even when matching on clinical features [6, 7, 9]. 
Genes that are both differentially expressed by race in tumors, and confer a survival 
disadvantage could explain a portion of the observed racial survival disparity, although to 
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date no study had evaluated whether race-associated genes conferred a survival 
disadvantage. To elucidate biological factors that predispose AA women to worse mortality 
outcomes, the current study showed that race-associated genes affect survival across 
multiple datasets.
Six candidate genes (CRYBB2, PSPH, ACOX2, MUC1, SQLE, TYMS) emerged from our 
analysis as both race- and survival- associated. Some of these genes have known biological 
functions, while others do not. Although AMFR tumor expression was, and has been 
previously shown to be associated with race [8], its expression is not associated with a 
survival advantage, suggesting that its differential expression may not contribute to racial 
mortality disparities. In contrast, we replicated the association between CRYBB2 [6, 8, 9, 
21, 22] and PSPH [21, 23] tumor expression and race, and also found that higher expression 
is associated with poorer survival. CRYBB2 encodes for the beta-crystallin B2 protein 
located at 22q11.23. Genetic variation in CRYBB2 is associated with macular degeneration 
[24], but the protein has no documented or hypothesized role in carcinogenesis. PSPH 
(Phosposerine-phosphotase, 7p11.2) is located near a region where gain of function is 
associated with advanced prostate tumor stage [25]. This gene has also been implicated in 
metabolism [26]. An emerging hallmark of cancer [27], the “Warburg effect”, is the ability 
of cancer cells to thrive in an oxygenated environment through glycolysis. Based on 
candidate gene studies of genes involved in cellular metabolism, Kim et al [26] found that 
PSPH expression was higher in basal-like tumors than in Luminal A tumors, and that high 
expression was associated with poor survival, HR = 2.07, 95% CI = (1.10, 4.18), an effect 
size similar to what we found here.
There is limited literature on ACOX2 (acyl-CoA oxidase 2, branched chain, 3p14.3), but 
there may be a genetic variant that is a shared risk factor for preeclampsia and 
cardiovascular disease [28], and some evidence that a transcript is associated with 
hepatocellular carcinoma [29]. ACOX2 up-regulation in the tumor conferred the same 
protective effect on mortality as MUC1 (mucin 1, cell surface associated 1q21). Variants of 
MUC1 interact with estrogen [30], and higher expression is associated with late stage 
epithelial ovarian cancer [31, 32] and prostate cancer [33].
Although little has been documented about the role that SQLE (squalene epoxidase, 8q24.1) 
plays in breast cancer progression, one study found that SQLE mRNA expression was 
inversely associated with survival among ER+ stage 1 or 2 patients [34]; this parallels our 
results that increased expression in tumor tissue is associated with almost a 2-fold increase 
in mortality in the NKI295 dataset. High TYMS (thymidylate synthetase, 18p11.32) 
expression was the largest independent predictor of mortality in our analysis. TYMS is 
associated with tumor proliferation, and is one of the 50 genes whose expression is used to 
classify breast cancer into intrinsic subtype [17]. Genetic variants of TYMS or its expression 
predict sensitivity to 5-fluorouracil [35–37], are prognostic factors for lymph node 
infiltration in CRC patients [38], and lower expression of TYMS is a positive prognostic 
factor for non-small cell lung cancer [39].
Disparities in survival may result from the joint expression of multiple genes, rather than 
from a single gene. Our MRE score captured the cumulative effects of multiple genes and 
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showed that high MRE points were associated with worse outcomes in both our training and 
test datasets. This score was also positively correlated with tumor proliferation score, 
providing independent confirmation of biological relevance. However, this score should not 
be considered as a substitute for established prognostic markers such as intrinsic subtype. 
After controlling for intrinsic subtype, the MRE score was not statistically significantly 
associated with breast cancer survival in either the UNC/NKI dataset or the METABRIC 
data, and generally appears to be higher in in basal-like and luminal B tumors. A major 
limitation to our study is that we were not sufficiently powered to evaluate subtype specific 
survival advantages associated with the MRE score. For instance, there were only 7 
METABRIC luminal A individuals with an MRE score higher than 3. The direction of effect 
is also unknown: these genes may increase probability of progressing to a more aggressive 
subtype, or more aggressive subtypes may have increased probability of upregulating these 
genes. These two possibilities cannot be evaluated in human tumor specimens that are 
sampled only at a single point in time. However, future research identifying the mechanism 
of action of the genes in the MRE score could help establish their biological relevance.
Although some disparities in luminal A breast cancer mortality may be attributable to 
treatment or access to care, the patterns of expression of these genes in the continuum of 
normal to malignancy suggest that intrinsic biological differences between at-risk AA and 
CAU women may also be operating, and these patterns guide our interpretations of the data. 
Furthermore, because CRYBB2 and PSPH expression were elevated in both normal and 
tumor tissue of AA compared with CAU, racial differences likely exist from the earliest 
stages of tumor development. Previous studies have suggested that PSPHL (a PSPH 
homolog) and CRYBB2 were differentially expressed in normal tissue of AA and CAU 
women who underwent reduction mammoplasty (N=6) or those without evidence of a 
malignancy (N=19) [6]. These investigators posited that SNP rs6700—located close to 
PSPHL—may explain the differences in expression, since the minor allele frequency of AA 
is higher compared with CAU. We note that future studies using RNAseq should evaluate 
the specific transcripts of PSPH and CRYBB2 with respect to race, because recent studies 
[40, 41] suggest that these genes have significant homology to pseudogenes that could 
produce signal on a microarray. Additionally, Sturtz et al [41] concluded that the PSPHL 
disparity signal observed in several studies may be due to population stratification.
Breast cancer mortality disparities are likely driven by a number of social and biological 
forces. Uncovering the factors that drive disparities is complicated and necessitates 
evaluating the problem from many different vantage points. Replication of findings across 
multiple study populations, and by investigators using different analytical and technical 
approaches, strengthens the evidence in support of these genes as possible targets. 
Continued evaluation of genes that differ by race in both tumor and normal, such as 
CRYBB2 and PSPH, as candidate markers of race-associated disparities should include 
larger population-based studies. Mechanistic studies are also needed, especially for 
CRYBB2, which has now been shown to associate with race and survival in multiple 
studies.
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Fig. 1. Two-dimensional cluster of race-associated gene expression
All genes (rows) were median-centered across the samples (columns). AA women are 
represented by black boxes immediately above the heatmap and CAU women with white 
boxes. There are two distinct gene clusters with the orange cluster including primarily AA 
and the purple cluster including primarily CAU.
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Fig. 2. Median-centered gene expression across samples, stratified by race and tissue type 
(normal, adjacent normal, tumor) for race- and survival-associated (disparity score) genes
There are two distinct patterns of expression. In figures a–d, expression is most distinct by 
race among tumors, whereas levels are similar by race in normal tissue; In figures e and f, 
however, CRYBB2 (e) and PSPH (f) levels are higher even in normal tissue of AA women. 
The increased expression persists in tumor..
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Fig. 3. Top: Boxplots showing the distribution of disparity score by subtype and by race
Disparity scores are highest for basal-like, HER2, and Luminal B tumors in both test 
(METABRIC, a) and training (UNC337 + NKI295, b) data. Across all tumors (c), disparity 
scores are higher in African Americans, but these differences are not solely driven by 
subtype because expression is higher even among Luminal A tumors only (d).
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Fig. 4. Survival curves and corresponding Hazard Ratios (HR) by disparity score
(bottom 25%, middle 50%, top 25%) in the training data (a) and test data: overall (b), 
Luminal A/B (c) only, and Luminal A only (d).
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Table 2
Demographic and tumor characteristics of UNC337
Caucasian N=108 (%) African American N=57 (%) P value
Age (years)
 < 40 12 (11) 8 (14)
 40–49 27 (25) 14 (25)
 >=50 69 (64) 35 (61)
 Missing 0 0
p = 0.86
Tumor Size
 <2 cm 33 (31) 11 (19)
 >= 2 cm 71 (66) 42 (74)
 Missing 4 (4) 4 (7)
p = 0.21
Tumor grade
 well (1) 12 (11) 2 (4)
 moderate (2) 39 (36) 17 (30)
 poor (3) 50 (46) 35 (61)
 Missing 7 (6) 3 (5)
p = 0.10
ER status
 Positive 70 (65) 26 (46)
 Negative 34 (31) 30 (53)
 Missing 4 (4) 1 (2)
p = 0.02
PR status
 Positive 48 (44) 20 (35)
 Negative 43 (40) 27 (47)
 Missing 17 (16) 10 (18)
p = 0.34
Node status
 Negative 59 (55) 21 (37)
 Positive 45 (42) 34 (60)
 Missing 4 (4) 2 (4)
p = 0.03
Subtype
 Basal 21 (19) 18 (32)
 Her2 13 (12) 6 (11)
 Lum A 49 (45) 19 (33)
 Lum B 17 (16) 11 (19)
 Normal 8 (7) 3 (5)
 Missing 0 0
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Caucasian N=108 (%) African American N=57 (%) P value
P = 0.38
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Table 4
Hazard ratios comparing in NKI295 and average gene expression in UNC337 tumors.
Gene HR (95% CI) Median expression overall (UNC337) Median expression: AA Median expression: CAU
ACOX2 0.65 (0.42, 1.02) 0.403 −0.046 1.058
CRYBB2 1.36 (0.87, 2.13) −0.011 0.794 −0.237
MUC1 0.65 (0.42, 1.02) 2.306 1.437 2.5165
PSPH 1.65 (1.05, 2.58) −0.864 0.036 −1.3275
SQLE 1.98 (1.25, 3.14) −1.37 −0.84 −1.596
TYMS 2.67 (1.65, 4.32) −2.67 −2.57 −2.845
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Table 5
Multivariable Hazard Ratios for MRE Score
NKI + UNC337 METABRIC
Model HR (95% CI) p-value HR (95% CI) p-value
MRE Score 1.19 (1.12, 1.27) 2.4E-08 1.06 (1.04, 1.09) 3.7E-06
MRE Score + clinical 1.11 (1.03, 1.19) 0.0040 1.05 (1.02, 1.08) 0.0004
MRE Score + clinical + subtype 1.07 (0.99, 1.16) 0.08 0.99 (0.96, 1.02) 0.46
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